Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.

Abstract

The aim of the present study was to develop a new therapeutic drug to improve the prognosis of ovarian cancer patients. Human urokinase-type plasminogen activator (uPA)17-34-kunitz-type protease inhibitor (KPI) eukaryotic expression vector was constructed and recombinant human uPA17-34-KPI (rhuPA17-34-KPI) in P. pastoris was expressed. In the present study, the DNA sequences that encode uPA 17-34 amino acids were created according to the native amino acids sequence and inserted into the KPI-pPICZαC vector, which was constructed. Then, uPA17‑34-KPI-pPICZαC was transformed into P. pastoris X-33, and rhuPA17-34-KPI was expressed by induction of methanol. The bioactivities of a recombinant fusion protein were detected with trypsin inhibition analysis, and the inhibitory effects on the growth of ovarian cancer cells were identified using the TUNEL assay, in vitro wound‑healing assay and Matrigel model analysis. The results of the DNA sequence analysis of the recombinant vector uPA17-34-KPI‑pPICZα demonstrated that the DNA‑encoding human uPA 17-34 amino acids, 285-288 amino acids of amyloid precursor protein (APP) and 1-57 amino acids of KPI were correctly inserted into the pPICZαC vector. Following induction by methonal, the fusion protein with a molecular weight of 8.8 kDa was observed using SDS-PAGE and western blot analysis. RhuPA17-34-KPI was expressed in P. pastoris with a yield of 50 mg/l in a 50-ml tube. The recombinant fusion protein was able to inhibit the activity of trypsin, inhibit growth and induce apoptosis of SKOV3 cells, and inhibit the invasion and metastasis of ovarian cancer cells. By considering uPA17-34 amino acid specific binding uPAR as the targeted part of fusion protein and utilizing the serine protease inhibitor activity of KPI, it was found that the recombinant fusion protein uPA17-34-KPI inhibited the invasion and metastasis of ovarian tumors, and may therefore be regarded as effective in targeted treatment.

• Authors: Manman Su, Weiqin Chang, Dingding Wang, Manhua Cui, Yang Lin, Shuying Wu, Tianmin Xu
• Journal: Oncology reports (Oncol Rep) Vol. 34 Issue 3 Pg. 1337-44 (Sep 2015) ISSN: 1791-2431 [Electronic] Greece
• PMID: 26166362 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Drug Combinations
• Laminin
• Proteoglycans
• Receptors, Urokinase Plasminogen Activator
• Recombinant Fusion Proteins
• Recombinant Proteins
• recombinant Kunitz protease inhibitor
• matrigel
• Collagen
• Aprotinin
• Urokinase-Type Plasminogen Activator

Topics

• Amino Acid Sequence (genetics)
• Apoptosis (drug effects, genetics)
• Aprotinin (administration & dosage, genetics)
• Cell Line, Tumor
• Cell Proliferation (drug effects, genetics)
• Collagen
• Drug Combinations
• Female
• Gene Expression Regulation, Neoplastic
• Genetic Vectors
• Humans
• Laminin
• Ovarian Neoplasms (genetics, pathology, therapy)
• Proteoglycans
• Receptors, Urokinase Plasminogen Activator (genetics)
• Recombinant Fusion Proteins (administration & dosage, genetics)
• Recombinant Proteins (administration & dosage, genetics)
• Urokinase-Type Plasminogen Activator (administration & dosage, genetics)